Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 2, 2011, Pages 125-130

  Hansen, Nicole L ^a   Chandiramani, Divya V ^b   Morse, Michael A ^a   Wei, David ^b   Hedrick, Nancy E ^a   Hansen, Richard A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b University of North Carolina   (United States)

Author keywords

cetuximab; hypersensitivity; observational; predictors

Indexed keywords

CETUXIMAB;

ADULT; ALLERGY; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; COLON CANCER; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; EMERGENCY WARD; FEMALE; HEAD AND NECK CANCER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MORBIDITY; PREMEDICATION; PRIORITY JOURNAL; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG HYPERSENSITIVITY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASMS; NORTH CAROLINA; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 79960517479     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155209360853     Document Type: Article

References (18)

1. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D., Au HJ et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007 ; 357 (20). 2040-8. (Pubitemid 350106711)
2. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 ; 351 (4). 337-45. (Pubitemid 38944402)
3. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001 ; 37 (suppl 4). S16-22.
4. Bonner JA, Harari PM, Giralt J., Azarnia N., Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 ; 354 (6). 567-78. (Pubitemid 43209104)
5. Emanuel EJ The cost of marginal medicine is too high. MedGenMed 2005 ; 7 (4). 67.
6. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004 ; 351 (4). 317-9. (Pubitemid 38944397)
7. Chung KY, Shia J., Kemeny NE, Shah M., Schwartz GK, Tse A. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005 ; 23 (9). 1803-10. (Pubitemid 46211358)
8. Chung CH, Mirakhur B., Chan E., Le QT, Berlin J., Morse M. et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008 ; 358 (11). 1109-17. (Pubitemid 351398485)
9. O'Neil BH, Allen R., Spigel DR, Stinchcombe TE, Moore DT, Berlin JD et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007 ; 25 (24). 3644-8. (Pubitemid 47372602)
10. George TJ, Laplant KD, Davis AB Risk factors and incidence of cetuximab hypersensitivity reactions: A Veterans Affairs experience. In: 2009 Gastrointestinal Cancers Symposium, American Society of Clinical Oncology, San Francisco, California, 2009.
11. Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., Knecht R. et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol 2004 ; 22 (14). 488 s.
12. National Cancer Institute. Essential elements of a data and safety monitoring plan for clinical trials funded by the National Cancer Institute. US; National Cancer Institute, 2001.
13. What are the key statistics for colorectal cancer? 2008. Available at: http://www.cancer.org/docroot/CRI/content/CRI-2-4-1X-What-are-the-key- statistics-for-colon-and-rectum-cancer.asp?sitearea (accessed date April 8, 2009 ).
14. American Cancer Society. Cancer facts and figures. Atlanta, GA ; American Cancer Society, 2009.
15. Du B., Altorki NK, Kopelovich L., Subbaramaiah K., Dannenberg AJ Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism. Cancer Res 2005 ; 65 (13). 5982-8. (Pubitemid 40911206)
16. Kalyankrishna S., Grandis JR Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006 ; 24 (17). 2666-72. (Pubitemid 46622088)
17. Nelson R. Hypersensitivity reactions to cetuximab related to IgE antibodies against oligosaccharides. N Engl J Med 2008 ; 358: 1109-17.
18. Van Gerpen R. Chemotherapy and biotherapy-induced hypersensitivity reactions. J Infus Nurs 2009 ; 32 (3). 157-65.